In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine

Kar Muthumani(The Wistar Institute), David B. Weiner(The Wistar Institute), Hyeree Choi(The Wistar Institute), Laurent Humeau(Inovio Pharmaceuticals (United States)), Trina Racine(University of Saskatchewan), Charles C. Reed(Inovio Pharmaceuticals (United States)), Young K. Park(Kolon Life Science (South Korea)), Elizabeth K. Duperret(The Wistar Institute), Jingjing Jiang(Hebei Medical University), Sangya Agarwal(Amgen (United States)), Christopher Chung(Northwestern University), Joel N. Maslow(Kolon Life Science (South Korea)), Kenneth E. Ugen(University of South Florida), Matthew P. Morrow(Inovio Pharmaceuticals (United States)), Bryan D. Griffin(Sunnybrook Hospital), Niranjan Y. Sardesai(Io Therapeutics (United States)), Emma L. Reuschel(The Wistar Institute), Gary Kobinger(Global Affairs Canada), Amir Sada Khan(COMSATS University Islamabad), J Joseph Kim(Inovio Pharmaceuticals (United States)), Kate E. Broderick(Inovio Pharmaceuticals (United States)), Stephanie Ramos(Inovio Pharmaceuticals (United States)), Kimberly A. Kraynyak(Inovio Pharmaceuticals (United States)), Jian Yan(Inovio Pharmaceuticals (United States)), Sagar B. Kudchodkar(The Wistar Institute), Amelia A. Keaton(Children's Hospital of Philadelphia), Stephanie A. Booth(Manitoba Health), Brian Lee(Sisters of Mercy Health System), Yinho K Kim(The Wistar Institute)
npj Vaccines
November 10, 2016
Cited by 136


Related Papers